Background
Materials and methods
Study ethics
Patients
Characteristics | Value |
---|---|
Age: Mean ± SD ( range ) years old | 65.8 ± 8.39 (50–82 ) |
SEX M:F | 21:20 |
Indications for referrals(n) | |
Primary lung cancer post operation | 20 |
Extrapulmonary malignancy with pathology proved lung metastases | 15(8 colon,7 other locationa) |
Growing lung nodule with cancer history | 6 (2 colon cancers,4 lung cancers) |
Cryoablation procedure
Safety and procedure related complication
Follow up protocols and treatment response evaluation
Statistics
Statistical analysis
Results
Patients and CA procedures
Characteristics | Value |
---|---|
Number of tumors | 73 |
Number of Procedures | 62 |
Numbers of Needles Used Per Tumor Mean ± SD (range) | 1.5 ± 0.84(1–4) |
Number of Tumors Treated In One Procedure, Mean ± SD (range) | 1.16 ± 0.37(1–2) |
Number of Tumors Treated Per Patient, Mean ± SD (range) | 1.49 ± 1.05 (1–6) |
Mean Tumor Diameter ± SD ( range ) cm | 1.48 ± 1.22(0.4–6.7a) |
Mean Procedure Time ± SD (range), minutes | 103.24 ± 38.3(58–232b) |
Mean Days of Post Procedure Hospital Stay, days (range) | 2.27(1–11) |
Complication of CA Procedure | |
Rate of Pneumothorax Per Procedure | 51.6% (32/62) |
Rate of Pigtail Drainage For Each Episode of Pneumothorax | 21.8% (7/32) |
Rate of Pigtail Drainage for pneumothorax per procedure | 11.3% (7/62) |
Rate of Hemoptysis Per Procedure | 12.9% (8/62) |
CA procedure related complications
The survival analysis and therapeutic effect evaluation
Discussion
Survival and tumor control rates
StudiesRef no
| Moore,et al. [19] | SOLSTICE [27] | This Study | Leppel-mann, et al. [25] | Yashiro, et al. [15] | Inoue, et al. [22] | |
---|---|---|---|---|---|---|---|
Patient numbers
| 45 | 40 | 128 | 41 | 10 | 71 | 117 |
Origin of Targets: nodules = mixed origin
| lung | mets | mets | nodules | Head and neck mets | nodules | nodules |
Mean tumor size(cm)
| 1.9 | 1.4 | 1.0 ± 0.6 | 1.48 | 1.6 | 1.28 | 1.4 |
Follow up protocol: baseline/ months after baseline
| 1 M/3 M | 3 M/3 M | 1 M/3 M | 3 M/3 M | 1 day or 1 M/3 M | 1 M/3 M | 1WK or 1 M/3 M |
Anesthesia Methods
(LA local anesthesia
GA General anesthesia)
| GA | GA67% conscious sedation 33% | GA 69% Conscious Sedation 29% LA 2% | LA | Concious Sedation/GA | Pentazzo-cine+ Atropine + LA | LA |
needle size(Gauge/G)
| 13G/ 16G | 17G/13G | 17G /15G/ 13G | 17G | 16G | 15G | 13G/ 12G |
Pneumothorax per procedure %
(N/A non applicable)
| 51 | N/A | N/A | 52 | 38.2 | N/A | 61.7 |
Pneumothorax require drainage per procedure% (N/A non applicable)
| 12.8 | 18.8 | 26 | 11.3 | 14.3 | N/A | 17.6 |
Hemoptysis per procedure % (N/A non applicable)
| 40 | N/A | N/A | 12.9 | 33.3 | N/A | 36.8 |
Overall Survival 1year%
| 89.4 | 97.5 | 97.6 | 97 | N/A | N/A | N/A |
Overall Survival 2year%
| Around > 85a
| 84.3 | 86.6 | 94 | N/A | N/A | N/A |
Overall Survival 3 year%
| 78.1 | 63.2 | N/A | 82 | N/A | N/A | N/A |
Overall Survival 5 year%
| 67.8 | 46.7 | N/A | N/A | N/A | N/A | N/A |
Response Criteria
| Radiology &PET | M-RECIST | M-RECIST | M-RECIST | PET/CT and CT | Nadir+/- CEb
| N/A |
Tumor progression free rate 1Y%
| N/A | 94.2 | 85.1 | 86.2 | 88(estimated) | 80.4 | N/A |
Tumor progression free rate 2Y%
| N/A | N/A | 77.2 | 77 | 65(estimated) | 69.0 | N/A |
Tumor progression free rate 3Y%
| N/A | 83.3 | N/A | 74 | N/A | 67.7 | N/A |
Tumor progression free rate 5Y%
| 63.8c
| 75 | N/A | N/A | N/A | N/A | N/A |